Savara, Inc. (SVRA)
SVRA moved a median of 0.00% 30 minutes after news, and -0.14% by the close. How SVRA actually reacts to news — the realized, point-in-time move the market made, measured across 1,030 labeled events over the last three years with zero look-ahead.
SVRA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 1,026 |
| 30-min | 0.00% | 46% | 1,029 |
| 60-min | 0.00% | 50% | 1,029 |
| to close | -0.14% | 46% | 1,027 |
| Middle 50% of SVRA reactions | -0.76% to +0.80% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 1,030 |
Half of all Savara, Inc. news events land between -0.76% and +0.80% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SVRA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 13 | +0.80% | 62% | +0.54% |
| Rating reiterations | 51 | 0.00% | 49% | -0.34% |
| Price-target raises | 12 | +0.39% | 58% | +0.04% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how SVRA ranks against every other measured name →
That’s how SVRA usually reacts — get an email when it moves on news →Email me when SVRA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SVRA's baseline. Nothing else.
Recent SVRA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026 | Press release | Business Wire | +0.62% | -1.24% | |
| Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | Press release | Business Wire | +0.09% | -1.58% | |
| Savara Announces New Employment Inducement Grant | Press release | Business Wire | +0.36% | +0.90% | |
| Form 10-Q Savara Inc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.71% | -3.55% | |
| Form S-8 Savara Inc | SEC filing · Form S-8 | SEC EDGAR | -2.71% | -3.55% | |
| Savara Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | Business Wire | -2.71% | -3.55% | |
| Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 | Press release | Business Wire | +0.94% | +4.33% | |
| Savara Announces New Employment Inducement Grant | Press release | Business Wire | +0.74% | -0.74% | |
| Form 8-K Savara Inc For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -1.20% | |
| Savara Announces Chief Financial and Administrative Officer Transition | Press release | Business Wire | -1.50% | -1.20% | |
| Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference | Press release | Business Wire | +0.68% | -1.74% | |
| Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 | Press release | Business Wire | +2.12% | +7.63% | |
| Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | Press release | Business Wire | -0.10% | -1.36% | |
| Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | Press release | Business Wire | +0.30% | -1.80% | |
| Form 10-Q Savara Inc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.66% | +9.34% | |
| Savara Reports First Quarter Financial Results and Provides Business Update | Press release | Business Wire | +1.66% | +9.34% | |
| Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference | Press release | Business Wire | +0.12% | -1.17% | |
| Form ARS Savara Inc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +2.97% | +1.38% | |
| Form DEF 14A Savara Inc For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +2.97% | +1.38% | |
| Form DEFA14A Savara Inc | SEC filing · Form DEFA14A | SEC EDGAR | +2.97% | +1.38% | |
| Savara Announces New Employment Inducement Grant | Press release | Business Wire | -2.05% | -3.44% | |
| Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | Press release | Business Wire | +1.29% | -2.59% | |
| Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference | Press release | Business Wire | +1.84% | +1.68% | |
| Form PRE 14A Savara Inc For: Jun 04 | SEC filing · Form PRE | SEC EDGAR | +1.94% | +4.22% | |
| Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | Press release | Business Wire | -0.35% | +1.05% | |
| Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | Press release | Business Wire | -0.88% | -1.75% | |
| Form 10-K Savara Inc For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.75% | -1.32% | |
| Form 8-K Savara Inc For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +0.75% | -1.32% | |
| Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update | Press release | Business Wire | +0.75% | -1.32% | |
| Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | Press release | Business Wire | +3.12% | +5.85% | |
| Savara Announces Participation in 2026 Citizens Life Sciences Conference | Press release | Business Wire | +0.45% | -1.44% | |
| Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | Press release | Business Wire | +0.27% | +2.15% | |
| Savara Announces New Employment Inducement Grant | Press release | Business Wire | +1.45% | +3.80% | |
| Savara Announces Participation in Upcoming Investor Healthcare Conferences | Press release | Business Wire | +1.69% | -3.37% | |
| Form 8-K Savara Inc For: Jan 26 | SEC filing · Form 8-K | SEC EDGAR | +1.73% | +1.21% | |
| Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* | Press release | Business Wire | +1.73% | +1.21% | |
| Savara Announces New Employment Inducement Grant | Press release | Business Wire | +0.53% | +4.92% | |
| Form 8-K Savara Inc For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +0.52% | +0.17% | |
| PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* | Press release | Business Wire | +0.52% | +0.17% | |
| Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | Press release | Business Wire | +1.34% | +8.19% | |
| Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +1.08% | -5.27% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Savara Inc. (SVRA) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.22% | +1.69% | |
| Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* | Press release | Business Wire | +1.42% | +3.74% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Savara Inc. (SVRA) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.15% | -0.23% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Savara Inc. (SVRA) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +1.22% | -1.22% | |
| Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System | Press release | Business Wire | -1.45% | -0.68% | |
| Savara Inc. (SVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +4.01% | +1.92% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Savara Inc. (SVRA) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | -0.48% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Savara Inc. (SVRA) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.84% | -1.79% | |
| Savara Announces Participation in Upcoming Investor Healthcare Conferences | Press release | Business Wire | +0.54% | +5.58% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SVRA section they belong to.
Where else SVRA is measured.
SVRA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GraniteShares YieldBOOST CRCL ETF (CRY) | 1,038 | 0.00% | 49% |
| Canopy Growth Corporation - Common Shares (CGC) | 1,033 | -0.77% | 37% |
| INTREXON CORP (XON) | 1,025 | +0.05% | 52% |
| Ardelyx, Inc. (ARDX) | 1,024 | -0.09% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Savara, Inc.'s median reaction calculated?
Every labeled SVRA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,030 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of SVRA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SVRA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.